AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02642848 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: HTO with microfracture
Description: High tibial osteotomy(HTO) with micro fracture on femoral condyle is an common treatment for the correction of malalignment of the knee treating osteoarthritis. Device: Tomofix
Study NCT02642848 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transplantation of bone marrow stem cell
Description: Transplantation of autologous bone marrow cell concentrate using BMAC collecting from iliac bone. Bone marrow cell cell 6cc
Study NCT02642848 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transplantation of adipose derived stem cell
Description: Transplantation of autologous adipose-derived stromal vascular fraction using LipoSculptor collecting from abdominal fat tissue. Adipose derived stem cell from abdominal fat tissue 3cc
Study NCT04142957 — intervention group
Intervention type: OTHER
Intervention: COPD Pal
Description: 'COPD Pal' aims to allow people with COPD to track and manage their condition. It enables patients to log symptoms (e.g. COPD assessment Test), wellness (e.g. quality of life such as EQ-5D), and medications, to help them become more engaged in their own care.
Study NCT03121287 — intervention group
Intervention type: OTHER
Intervention: Imaging Biomarkers
Description: Whole lung volumetric CT scans
Study NCT03767855 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CK-3773274 - Granules in Capsule
Description: CK-3773274 formulated as granules in capsule
Study NCT02077491 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High-protein diet and resistance training
Description: The intervention includes 1.7g/kg/day during admission combined with resistance training and a daily protein and energy supplement after discharge.
Study NCT02668172 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pasireotide LAR 60 mg
Description: as mono-therapy or in combination with pegvisomant
Study NCT03121287 — intervention group
Intervention type: OTHER
Intervention: Pulmonary
Description: Pulmonary Function Tests \& 6 minute hall walk
Study NCT02668172 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegvisomant
Description: only in combination with pasireotide LAR
Study NCT03121807 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oliclinomel N4 Per bag 1.5 L
Description: Home parenteral nutrition with 910 kcal/day , including 33 g amino acid/day, 120 g glucose/day, 30 g lipid/day and electrolyte, micro-element and vitamin according to the nutritional status of subjects and followed the standard procedure of the hospital (Oliclinomel N4 Per bag 1.5 L), was infused continuously daily in an infusion time ranged between 18-24 hours.
Study NCT03121807 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Study NCT03121807 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5Fluorouracil
Study NCT03121807 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Study NCT00047853 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Shock device
Description: A participant could receive a shock or not receive as shock
Study NCT00047853 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acoustic startle
Description: Acoustic startle for MEG only
Study NCT03438760 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Science + Phonological Awareness
Description: The goal is to facilitate phonological awareness during science lessons. Because phonological awareness does not relate to science learning, this is a placebo.
Study NCT03438760 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Science + Grammar Intervention
Description: The goal is to facilitate science learning by providing models, prompts, and experiences with grammatical structures related to science processes.
Study NCT03438760 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Science + Vocabulary Intervention
Description: The goal is to facilitate science learning by providing models, prompts, and experiences with vocabulary related to science processes.
Study NCT01091142 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NP001
Description: Cohort 1: 0.3 mg/kg NP001(6:2 active:placebo) Cohort 2: 1.1 mg/kg NP001(6:2 active:placebo) Cohort 3: 2.1 mg/kg NP001(6:2 active:placebo) Cohort 4: 4.3 mg/kg NP001(6:2 active:placebo)
Study NCT01091142 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Cohort 1: placebo Cohort 2: placebo Cohort 3: placebo Cohort 4: placebo
Study NCT03234270 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Core temperature measurements
Description: Core temperature measurements with coretemp pill
Study NCT03234270 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Core temperature measurements
Description: Core temperature measurements with coretemp pill
Study NCT01688999 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: 60 mg by mouth (PO) daily each 28 day cycle. Treatment continues until toxicity or disease progression.
Study NCT02768103 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: task-based training
Description: The 10-week training program is designed to incorporate requirements of motor learning and includes activities that require learning to coordinate the transferred Br with other synergists by producing pinch force in different upper limb postures and in a range of pinch openings. Biofeedback using a pinch dynamometer in self-selected postures provides feedback and knowledge of progress to the participant. A task board is used for practicing task-specific activities such as opening and closing zippers, using a remote, an ATM card, a key, and an electrical plug and focuses on pinch in dynamic conditions that require modulating force and maintaining specific positions. The pinch-pin device requires closing pinch-pins (clothes pin) of variable resistance ranging from approximately 1 to 8 lbs and placing them on rods arranged at different positions in the work space.
Study NCT01787955 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PPPD with Braun anastomosis
Description: making communication between E-loop and A-loop (Braun anastomosis 30cm away from duodenojejunostomy, by using staple method) will be added to conventional PPPD.
Study NCT01787955 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional PPPD
Study NCT03121287 — intervention group
Intervention type: OTHER
Intervention: Imaging
Description: Cardiac MRI
Study NCT03121287 — intervention group
Intervention type: OTHER
Intervention: Specimen Collection
Description: Blood draw
Study NCT03272061 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic-based exercise program
Description: Aerobic-based exercise will be carried out on a cycling ergometer three times a week for 30 minutes at 70% of the maximal workload. Every two weeks, the maximal workload will be reassessed, and training loads will be readjusted accordingly. Fully supervised training sessions will be performed with three-to-four study participants at a time. Subjects should maintain their body weight during the intervention period.
Study NCT00684489 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clinical hypertension specialist-no specific med. Any anti-hypertension meds.
Description: assignment to a clinical hypertension specialist. Drugs used were hypertension medications were: chlorothiazide, hydrochlorothiazide, polythiazide indapamide, metolazone, bumetanide, furosemide, torsemide, amiloride, triamterene, eplerenone, spironolactone, atenolol, betaxolol, bisoprolol, metoprolol, nadolol, propranolol, timolol, acebutolol, penbutolol pindolol, carvedilol, labetalol, benazepril, captopril, enalapril, fosinopril, lisinopril, moexipril, perindopril, quinapril, ramipril, trandolapril, candesartan, eprosartan, irbesartan, losartan, olmesartan, telmisartan, valsartan, diltiazem, dilacor, ditiazem, verapamil, amlodipine, felodipine, isradipine, nicardipine, nifedipine, nisoldipine, doxazosin, prazosin, terazosin, clonidine, clonidine patch, methyldopa, reserpine, guanfacine, hydralazine, minoxidil.
Study NCT00684489 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: renin guided therapeutics-no specific med. Any anti-hypertensive med.
Description: renin guided therapeutics-chlorothiazide, chlorthalidone, hydrochlorothiazide, polythiazide, indapamide, metolazone, bumetanide, furosemide, torsemide, amiloride, triamterene, eplerenone, spironolactone, atenolol, betaxolol, bisoprolol, metoprolol, nadolol, propranolol, timolol, acebutolol, penbutolol, pindolol, carvedilol, labetalol, benazepril, captopril, enalapril, fosinopril, lisinopril, moexipril, perindopril, quinapril, ramipril, trandolapril, candesartan, eprosartan, irbesartan, losartan, olmesartan, telmisartan, valsartan, diltiazem, dilacor, verapamil, amlodipine, felodipine, isradipine, nicardipine, nifedipine, nisoldipine, doxazosin, prazosin, terazosin, chlonidine, methyldopa, reserpine, guanfacine, hydralazine, minoxidil.
Study NCT03562520 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavior change counseling
Description: Core modules: 1 psychoeducation session at week 0; 4 behavior change counseling (BCC) sessions will occur at weeks 0, 4, 8, and 12; phone calls and/or texting sessions (weeks 1-3, 5-7, 9-11, and booster calls and/or texts on weeks 16 and 20) from therapists.~Optional modules: Exercise coaching sessions; family involvement options will include participation in any aspect of the intervention; peer support options will include: group exercise classes on site, online Fitbit groups where adolescents can participate in competitions with each other and provide motivational support, and fitness support groups facilitated by registered social workers.
Study NCT02951455 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Critical Dialogue
Description: Prompted by thematic images, aims to help participants develop a deeper understanding of how marginalizing processes (e.g., systematic stigma; feelings of rage as victims of discrimination) impact participants' lives and behavior.
Study NCT01716624 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxybutynin
Description: standard oral therapy
Study NCT01716624 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin A injection
Description: 10 units/kg injected into the detrusor muscle using cystoscopy
Study NCT00619112 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temozolomide
Description: single arm study
Study NCT00986518 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adaptive autologous cell immunotherapy
Description: each patient will undergo a blood cytapheresis to collect circulating lymphocytes. Ex-vivo cell sorting procedure will deplete patient's collected lymphocytes from regulatory T cells. Autologous Treg-depleted lymphocytes will be administered to the patient following a 5-day reduced intensity chemo-therapeutic conditioning.
Study NCT03882528 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Plasmodium falciparum malaria parasite
Description: Laboratory cultured Plasmodium falciparum strain 3D7 delivered via the bite of 5 infected mosquitoes with salivary gland scores of at least 2+ (11-100 sporozoites observed).
Study NCT01140555 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GYNECARE GYNOCCLUDE™
Description: GYNECARE GYNOCCLUDE™ Doppler Guided Uterine Artery Occlusion Device
Study NCT02041910 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Stem Cells
Description: MSCs injection intratesticular
Study NCT02041910 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Stem Cells
Description: 60 ml of Bone marrow will aspirated for stem cells isolation and preparation. 5 ml of stem cells prepared according to GMP rules injected into testis.
Study NCT03778658 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity Intervention
Description: Participants will engage in a multimodal aerobic and strength training intervention.
Study NCT03155386 — intervention group
Intervention type: OTHER
Intervention: Angiommamography
Description: A blinded central re-reading of the acquisition technique will be carried out by 3 radiologists (2 seniors and 1 junior) who will evaluate:~* The intensity of lesion enhancement~* The presence and type of artefacts on the recombined images.~* The quality of low-energy images according to recognized criteria for mammography.~The gold standard will be histology (biopsies or surgery) or follow-up to 1 year for non-biopsied benign lesions
Study NCT03895385 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bimekizumab
Description: Subjects will receive a single dose bimekizumab at a predefined time point during the Treatment Period.
Study NCT03767855 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - Granules in Capsule
Description: Placebo formulated as granules in capsule
Study NCT03767855 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CK-3773274 - Tablets
Description: CK-3773274 formulated as tablets
Study NCT04166773 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirzepatide
Description: Administered SC
Study NCT04166773 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC
Study NCT02908477 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Adjuvant Radiation Therapy
Description: 60 Gy / 2 Gy fractions (standard arm) 30 - 36 Gy / 1.5 - 1.8 Gy b.i.d. fractions (experimental arm)
Study NCT02908477 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Adjuvant Radiation Therapy
Description: 60 Gy / 2 Gy fractions (standard arm) 30 - 36 Gy / 1.5 - 1.8 Gy b.i.d. fractions (experimental arm)
Study NCT02908477 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 15 mg/m2. Experimental arm only.
Study NCT02908477 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: 40 mg/m2. Standard arm only.
Study NCT03159702 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evomela
Description: 140 mg/m\^2/day IV on Day -6 for patients who are \< 60 years of age. 70 mg/m\^2/day IV on Day -6 For patients who are ≥60 years or have a HCT-CI score of >3
Study NCT02951455 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Capacity Building Project
Description: Designed to create collaborative efforts to overcome and dismantle marginalizing processes by building positive social and organizational relationships and community capacity through the development and implementation of community projects aiming to address social determinants of health.
Study NCT02951455 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Quality of Life Wheel
Description: Aims to increase self-efficacy and help participants develop a vision for their future, breaking this vision down into small, feasible, measureable goals they can implement on a weekly basis (e.g. quitting smoking, improving relationships with family members, paying down debt).
Study NCT03279497 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health game
Description: Participants allocated to the Health game intervention group get to use the health game during the four week intervention period and participants are allowed to use it on their free time.
Study NCT03279497 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sport and fitness application
Description: Participants allocated to the Sport and fitness application intervention group get to use the sport and fitness application during the four week intervention period and participants are allowed to use it on their free time.
Study NCT01730066 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L. plantarum 299 and L. plantarum 299v (+maltodextrin)
Description: Patients will be given a mixture of maltodextrin ( a starch product often used i alimentary products) and two strains of probiotic bacteria ( L. plantarum 299 and L. plantarum 299v ) dissolved in water. They will gurgle and swallow the suspension from the day before surgery. Postoperatively they will be given the probiotic mixture via a nasogastric tubing twice a day and when the responsible surgeon find it suitable also orally as described above. When they can swallow no study product is given through the nasogastric tube.~Patients randomized 1:1 between groups
Study NCT02078336 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam Mylan
Study NCT02078336 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lorazepam Mylan
Study NCT02078336 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valium + Akineton + Dehydrobenzperidol + Atropine sulfate
Study NCT00725205 — intervention group
Intervention type: BIOLOGICAL
Intervention: PegIntron (Peginterferon alfa-2b)
Description: Peginterferon alfa-2b (injection pen) administered according to the product's labeling and current practice in Hungary (1.5 micrograms \[mcg\]/killogram \[kg\]) for 12 weeks. Those participants whose continued treatment was warranted beyond week 12 based on response received therapy for 24 or 48 weeks depending on the viral genotype.
Study NCT00725205 — intervention group
Intervention type: DRUG
Intervention: Rebetol (Ribavirin)
Description: Ribavirin capsules administered according to the product's labeling and current practice in Hungary (weight based daily) for 12 weeks. Those participants whose continued treatment was warranted beyond week 12 based on response received therapy for 24 or 48 weeks depending on the viral genotype.
Study NCT01584557 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tolvaptan or Samsca
Description: uncoated tablet, 30mg, once per day, for up to 7 days.
Study NCT01584557 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo or sugar pill
Description: sugar pill
Study NCT03159702 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 40 mg/ m\^2/day intravenous on Days: -5 -4, -3, -2
Study NCT00681590 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: cholecalciferol (vitamin D)
Description: 400 IU daily (low dose)
Study NCT02951455 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PF
Description: Whether the intervention is delivered by a peer facilitator.
Study NCT00681590 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: cholecalciferol (vitamin D)
Description: 2000 IU daily (high dose)
Study NCT03915353 — intervention group
Intervention type: OTHER
Intervention: No Intervention
Description: No Intervention
Study NCT02116608 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Betadine
Description: Apply locally as needed.
Study NCT02116608 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Silver Nitrate
Description: Arzol Silver Nitrate Applicators may be applied directly to mucous membranes and other moist surfaces. In the case of dry skin, the applicator tip should be dipped in water immediately before use. Apply carefully to the area to be treated.
Study NCT02116608 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocortisone Butyrate Cream, 1.0%
Description: Hydrocortisone butyrate cream, 1.0% should be applied to the affected area as a thin film two or three times daily depending on the severity of the condition.
Study NCT03043976 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Actigraph GT9X Link device
Description: Assessment of the level of physical activity of PH patients using the Actigraph GT9X Link device that includes a triaxial accelerometer and can be enabled to show on its display the number of steps taken for the day, so that it can also be used by the patients as a common pedometer.~Evaluation of the effects of an 8 week step count-based light touch training programme to see if activity can be increased
Study NCT03043976 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Actigraph GT9X Link device
Description: Assessment of the level of physical activity of PH patients using the Actigraph GT9X Link device that includes a triaxial accelerometer and can be enabled to show on its display the number of steps taken for the day, so that it can also be used by the patients as a common pedometer.~Evaluation of the effects of an 8 week step count-based light touch training programme to see if activity can be increased
Study NCT00922272 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPD489 (lisdexamfetamine dimesylate)
Description: oral, 20, 30, 40, 50, 60, or 70 mg once daily
Study NCT02951455 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LC
Description: Whether the intervention is delivered by a licensed clinician.
Study NCT01197781 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOSTAMATIN
Description: Oral tablets - single dose
Study NCT01197781 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Verapamil
Description: Oral tablets - administered 3 times daily over 4 days
Study NCT02708966 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gymnema Sylvestre
Description: Gymnema Sylvestre, 300mg capsules 2 times daily with the first bite of breakfast and dinner
Study NCT02708966 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, 300mg capsules 2 times daily with the first bite of breakfast and dinner
Study NCT03739736 — intervention group
Intervention type: OTHER
Intervention: Combination of TB/HIV prevention activities (arm A)
Description: The intervention consists in a package of combination TB/HIV prevention activities, including active case finding for TB and universal test and treat for HIV. In arm A ART was initiated regardless of CD4 count. The intervention was delivered over a period of four years (2014-2017) by community health workers within the The HPTN071(PopART) trial (NCT01900977)